OncoMatch/Clinical Trials/NCT06364267
Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.
Is NCT06364267 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Tamoxifen 10 MG and Exemestane 25 MG for breast cancer.
Treatment: Tamoxifen 10 MG · Exemestane 25 MG — The purpose of the study is to to compare low dose of exemestane (babyexe) versus low dose of tamoxifen (babytam) in terms of change of quality of life from baseline to 12 months.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 overexpression (>5%)
ER+ve (>5%) DCIS
Allowed: CHEK2 germline pathogenic/likely pathogenic variant
Known carriers of a germline pathogenic/likely pathogenetic variant in the following moderate penetrance genes (CHEK2 or ATM)
Allowed: ATM germline pathogenic/likely pathogenic variant
Known carriers of a germline pathogenic/likely pathogenetic variant in the following moderate penetrance genes (CHEK2 or ATM)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: breast-conserving therapy (lumpectomy with negative margins and radiotherapy) — DCIS
patients with DCIS should have undergone breast-conserving therapy i.e. lumpectomy to remove the tumor with negative surgical margins followed by radiotherapy
Cannot have received: antiestrogen
Prior use of antiestrogens within 12 months from the date of the trial consent form signature
Cannot have received: hormone replacement therapy
Use of hormone replacement therapy (HRT) within 3 months from the date of the trial consent form signature
Lab requirements
Blood counts
normal blood cell count
Kidney function
patients with moderate or severe renal impairment [excluded]
Liver function
normal liver function tests
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify